Notícias e Atividades da NGM Biopharmaceuticals

NGM Biopharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

NGM Biopharmaceuticals é uma empresa listada sob o símbolo NGM (US).

Veja o organograma con seus 54 executivos principais

Biografias mais buscadas da NGM Biopharmaceuticals

• David Woodhouse, Chief Executive Officer and Director
• Shelly Guyer, Director
• William Rieflin, Chairman of the Board

Recentes movimentos de executivos em NGM Biopharmaceuticals

• Wendy Yeh, ingressou na Companhia como Chief Medical Officer  (Notícia publicada em 6 de fevereiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da NGM Biopharmaceuticals.

NGM Biopharmaceuticals possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).

Popular M&A news in Biotecnologia

• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).
• Taiho Pharmaceutical has announced the acquisition of Araris Biotech  (publicado em 3 de abril de 2025).
• Maxion Therapeutics acaba de anunciar uma arrecadação de fundos de 72 milhões de dólares. (publicado em 3 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de NGM Biopharmaceuticals

• NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer | NGM Biopharmaceuticals, Inc.
• NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022 | NGM Biopharmaceuticals, Inc.
• NGM Bio to Participate in Upcoming Investor Conferences | NGM Biopharmaceuticals, Inc.
• NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022 | NGM Biopharmaceuticals, Inc.
• NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors | NGM Biopharmaceuticals, Inc.
• NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results | NGM Biopharmaceuticals, Inc.
• News | NGM Biopharmaceuticals, Inc.
• News | NGM Biopharmaceuticals, Inc.
• NGM Bio to Participate in Upcoming Investor Conferences | NGM Biopharmaceuticals, Inc.
• NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022 | NGM Biopharmaceuticals, Inc.
• View more press releases Close

Redes sociais sobre NGM Biopharmaceuticals

• NGM Biopharmaceuticals na Wikipedia, Google News e Yahoo Finance
• NGM Biopharmaceuticals na LinkedIn, Twitter e YouTube